An official website of the United States government
Home
Name
Imlunestrant
Alternate Names
Inluriyo
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
Estrogen receptor antagonist
NSC Number
None
Primary Site
breast
Histology
None
Remarks
On September 25, 2025, the FDA approved imlunestrant (Inluriyo), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Code if given as first line of therapy.
Code if given as first line of therapy.
Coding
Please see remarks for additional information
